Company intelligence / Profile preview

Dyameo

Limoges, Nouvelle-Aquitaine, Francedyameo.com ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Dyameo has developed a single-use endoscopic probe designed for the instantaneous in-vivo detection of cancerous cells. The technology aims to enable early discrimination between healthy and malignant tissue during endoscopic procedures. As of late 2021, the company had raised $1.13 million in seed funding to advance this product toward market launch. No clinical trial results or regulatory approvals are reported.

Therapeutic areas: Oncology
Modalities: DeviceDiagnostic deviceEndoscopic probe
Industry: Medical Imaging

Partnerships

Medevice SAS and Aquiti Gestion SAS via NACO fund participated as investors; no major pharma/biotech partnerships disclosed.

Beyond the preview

Go deeper on Dyameo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dyameo.

Explore the full profile